Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$-- Mln
Revenue (TTM)
$-- Mln
Net Profit (TTM)
$0 Mln
ROE
-0.4 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.9
Industry P/E
--
EV/EBITDA
1.8
Div. Yield
0 %
Debt to Equity
1.2
Book Value
$2.4
EPS
$-1
Face value
--
Shares outstanding
143,958,000
CFO
$1,206.89 Mln
EBITDA
$1,338.41 Mln
Net Profit
$894.84 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Maravai Lifesciences Holdings Inc (MRVI)
| -61.5 | 21.4 | -50.0 | -81.3 | -60.3 | -- | -- |
|
BSE Sensex
| 5.2 | 7.3 | 8.4 | 12.8 | 16.0 | 21.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
Maravai Lifesciences Holdings Inc (MRVI)
| -16.7 | -54.2 | -65.8 | 49.4 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Maravai Lifesciences Holdings Inc (MRVI)
|
2.1 | 723.4 | 259.2 | -144.9 | -82.5 | -39 | -- | 0.9 |
| 49.2 | 7,502.9 | 1,196.0 | 158.1 | 19.6 | 7.6 | 57.7 | 4.0 | |
| 101.7 | 6,297.4 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 18.4 | |
| 141.0 | 6,824.6 | 4,050.0 | 22.2 | 5.4 | 0.6 | 618.4 | 2.2 | |
| 56.4 | 10,350.6 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 45.4 | 12,304.8 | 2,168.7 | 521.3 | 31.8 | 23.1 | 25.4 | 4.5 | |
| 52.0 | 8,204.1 | 1,084.3 | 485.4 | 43.3 | 103.8 | 17.7 | 16.8 | |
| 305.7 | 8,384.8 | 2,156.6 | 416.4 | 15.6 | 56.5 | 22.3 | 14.1 | |
| 24.9 | 9,289.5 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 121.0 | 11,755.2 | 2,412.6 | 305.8 | 20.5 | 11.6 | 40.3 | 4.6 |
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia... Pacific, and Latin and Central America. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California. Address: 10770 Wateridge Circle, San Diego, CA, United States, 92121 Read more
Co-Founder & Executive Chairman
Mr. Carl W. Hull
Co-Founder & Executive Chairman
Mr. Carl W. Hull
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Maravai Lifesciences Holdings Inc (MRVI) stood at $ 1,008 Mln as on 31-Dec-24
The share price of Maravai Lifesciences Holdings Inc (MRVI) is $2.10 (NASDAQ) as of 16-May-2025 16:00 EDT. Maravai Lifesciences Holdings Inc (MRVI) has given a return of -60.29% in the last 3 years.
Maravai Lifesciences Holdings Inc (MRVI) has a market capitalisation of $ 723 Mln as on 15-May-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Maravai Lifesciences Holdings Inc (MRVI) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Maravai Lifesciences Holdings Inc (MRVI) and enter the required number of quantities and click on buy to purchase the shares of Maravai Lifesciences Holdings Inc (MRVI).
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California. Address: 10770 Wateridge Circle, San Diego, CA, United States, 92121
The CEO & director of Mr. Carl W. Hull. is Maravai Lifesciences Holdings Inc (MRVI), and CFO & Sr. VP is Mr. Carl W. Hull.
There is no promoter pledging in Maravai Lifesciences Holdings Inc (MRVI).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,230
|
|
|
1,176
|
|
|
1,035
|
|
|
929
|
|
|
838
|
|
|
820
|
|
|
750
|
|
|
682
|
|
|
630
|
| Maravai Lifesciences Holdings Inc (MRVI) | Ratios |
|---|---|
|
Return on equity(%)
|
-39.04
|
|
Operating margin(%)
|
-82.48
|
|
Net Margin(%)
|
-55.89
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Maravai Lifesciences Holdings Inc (MRVI) was $0 Mln.
$0.14
(
